Recent research and development of PLGA/PLA microspheres/nanoparticles: A review in scientific and industrial aspects

Abstract

Poly(D,L-lactic-co-glycolic acid) (PLGA)/poly(lactic acid) (PLA) microspheres/nanoparticles are one of the most successful drug delivery systems (DDS) in lab and clinic. Because of good biocompatibility and biodegradability, they can be used in various areas, such as long-term release system, vaccine adjuvant, tissue engineering, etc. There have been 15 products available on the US market, but the system still has many problems during development and manufacturing, such as wide size distribution, drug stability issues, and so on. Recently, many new and modified methods have been developed to overcome the above problems. Some of the methods are easy to scale up, and have been available on the market to achieve pilot scale or even industrial production scale. Furthermore, the relevant FDA guidance on the DDS is still incomplete, especially for abbreviated new drug application. In this review, we present some recent achievement of the PLGA/PLA microspheres/nanoparticles, and discuss some promising manufacturing methods. Finally, we focus on the current FDA guidance on the DDS. The review provides an overview on the development of the system in pharmaceutical industry.

Graphical abstract

Keywords

PLGA / microspheres / drug delivery system / stability / manufacturing

References

[1] Harvey A J, Kaestner S A, Sutter D E, Harvey N G, Mikszta J A, Pettis R J. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharmaceutical Research, 2011, 28(1): 107–116

[2] Nair L S, Laurencin C T. Biodegradable polymers as biomaterials. Progress in Polymer Science, 2007, 32(8-9): 762–798

[3] Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Advanced Drug Delivery Reviews, 1997, 28(1): 43–70

[4] Han F Y, Thurecht K J, Whittaker A K, Smith M T. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Frontiers in Pharmacology, 2016, 7: 185

[5] Washington M A, Swiner D J, Bell K R, Fedorchak M V, Little S R, Meyer T Y. The impact of monomer sequence and stereochemistry on the swelling and erosion of biodegradable poly(lactic-co-glycolic acid) matrices. Biomaterials, 2017, 117: 66–76

[6] Tomic I, Vidis-Millward A, Mueller-Zsigmondy M, Cardot J M. Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism. International Journal of Pharmaceutics, 2016, 505(1-2): 42–51

[7] Zhu G Z, Schwendeman S P. Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: Mechanism of stabilization by basic additives. Pharmaceutical Research, 2000, 17(3): 351–357

[8] Kwak H H, Shim W S, Choi M K, Son M K, Kim Y J, Yang H C, Kim T H, Lee G I, Kim B M, Kang S H, Development of a sustained-release recombinant human growth hormone formulation. Journal of Controlled Release, 2009, 137(2): 160–165

[9] Kim B S, Oh J M, Hyun H, Kim K S, Lee S H, Kim Y H, Park K, Lee H B, Kim M S. Insulin-loaded microcapsules for in vivo delivery. Molecular Pharmaceutics, 2009, 6(2): 353–365

[10] Kwak H H, Shim W S, Hwang S, Son M K, Kim Y J, Kim T H, Yoon Z H, Youn H J, Lee G I, Kang S H, Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharmaceutical Research, 2009, 26(11): 2504–2512

[11] Gaspar M C, Gregoire N, Sousa J J S, Pais A A C C, Lamarche I, Gobin P, Olivier J C, Marchand S, Couet W. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. European Journal of Pharmaceutical Sciences, 2016, 93: 184–191

[12] Feng T S, Tian H Y, Xu C N, Lin L, Xie Z G, Lam M H W, Liang H J, Chen X S. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88(3): 1086–1093

[13] Salama A H, Mahmoud A A, Kamel R. A novel method for preparing surface-modified fluocinolone acetonide loaded PLGA nanoparticles for ocular use: In vitro and in vivo evaluations. AAPS PharmSciTech, 2016, 17(5): 1159–1172

[14] Qi F, Wu J, Fan Q Z, He F, Tian G F, Yang T Y, Ma G H, Su Z G. Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability. Colloids and Surfaces. B, Biointerfaces, 2013, 112: 492–498

[15] Parumasivam T, Leung S S Y, Quan D H, Triccas J A, Britton W J, Chan H K. Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. European Journal of Pharmaceutical Sciences, 2016, 88: 1–11

[16] Nath S D, Son S, Sadiasa A, Min Y K, Lee B T. Preparation and characterization of PLGA microspheres by the electrospraying method for delivering simvastatin for bone regeneration. International Journal of Pharmaceutics, 2013, 443(1-2): 87–94

[17] Wong V G, Hu M W L. US Patent 6726918 B1, 2004-04-27

[18] Callanan D G, Gupta S, Boyer D S, Ciulla T A, Singer M A, Kuppermann B D, Liu C C, Li X Y, Hollander D A, Schiffman R M, Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology, 2013, 120(9): 1843–1851

[19] Villanueva J R, Bravo-Osuna I, Herrero-Vanrell R, Martinez I T M, Navarro M G. Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration. European Journal of Pharmaceutical Sciences, 2016, 92: 287–297

[20] Zhang W, Wang L, Liu Y, Chen X, Liu Q, Jia J, Yang T, Qiu S, Ma G. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials, 2014, 35(23): 6086–6097

[21] Zhang W F, Wang L Y, Yang T Y, Liu Y, Chen X M, Liu Q, Jia J L, Ma G H. Immunopotentiator-loaded polymeric microparticles as robust adjuvant to improve vaccine efficacy. Pharmaceutical Research, 2015, 32(9): 2837–2850

[22] Hidaka S. Conflicting effects by antibodies against connexin36 during the action of intracellular Cyclic-AMP onto electrical synapses of retinal ganglion cells. Journal of Integrative Neuroscience, 2016, 15(4): 571–591

[23] Pavot V, Berthet M, Resseguier J, Legaz S, Handke N, Gilbert S C, Paul S, Verrier B. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. Nanomedicine (London), 2014, 9(17): 2703–2718

[24] Liu Q, Chen X, Jia J, Zhang W, Yang T, Wang L, Ma G. pH-responsive poly(D,L-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response. ACS Nano, 2015, 9(5): 4925–4938

[25] Gentile P, Chiono V, Carmagnola I, Hatton P V. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. International Journal of Molecular Sciences, 2014, 15(3): 3640–3659

[26] Dhandayuthapani B, Yoshida Y, Maekawa T, Kumar D S. Polymeric scaffolds in tissue engineering application: A review. International Journal of Polymer Science, 2011, 2011

[27] Wang Q, Gu Z, Jamal S, Detamore M S, Berkland C. Hybrid hydroxyapatite nanoparticle colloidal gels are injectable fillers for bone tissue engineering. Tissue Engineering. Part A, 2013, 19(23-24): 2586–2593

[28] Wang X, Wu X, Xing H L, Zhang G L, Shi Q, E L, Liu N, Yang T, Wang D, Qi F, Wang L, Liu H. Porous nanohydroxyapatite/collagen scaffolds loading insulin PLGA particles for restoration of critical size bone defect. ACS Applied Materials & Interfaces, 2017, 9(13): 11380–11391

[29] Reszko A E, Sadick N S, Magro C M, Farber J. Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatologic Surgery, 2009, 35(1): 380–384

[30] Valantin M A, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katlama C. Polylactic acid implants (New-Fill)((R)) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS (London, England), 2003, 17(17): 2471–2477

[31] Moyle G J, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, Mandalia S, Barton S E. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Medicine, 2004, 5(2): 82–87

[32] Lam S M, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): Technical considerations in soft-tissue contouring. Plastic and Reconstructive Surgery, 2006, 118(3 Suppl): 55s–63s

[33] Ghosh S, Sahu S, Agrawal L, Shiga T, Bandyopadhyay A. Inventing a co-axial atomic resolution patch clamp to study a single resonating protein complex and ultra-low power communication deep inside a living neuron cell. Journal of Integrative Neuroscience, 2016, 15(4): 403–433

[34] Gogolewski S, Jovanovic M, Perren S M, Dillon J G, Hughes M K. Tissue-response and in-vivo degradation of selected polyhydroxyacids-polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). Journal of Biomedical Materials Research, 1993, 27(9): 1135–1148

[35] Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky M D, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials, 2009, 30(10): 1947–1953

[36] Zhang T Z, Zhang Q Y, Chen J S, Fang K, Dou J, Gu N. The controllable preparation of porous PLGA microspheres by the oil/water emulsion method and its application in 3D culture of ovarian cancer cells. Colloids and Surfaces A-Physicochemical and Engineering Aspects, 2014, 452: 115–124

[37] Qi F, Wu J, Sun G Q, Nan F F, Ngai T, Ma G H. Systematic studies of Pickering emulsions stabilized by uniform-sized PLGA particles: Preparation and stabilization mechanism. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 2014, 2(43): 7605–7611

[38] Xia Y, Wu J, Wei W, Du Y, Wan T, Ma X, An W, Guo A, Miao C, Yue H, Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination. Nature Materials, 2018, 17(2): 187–194

[39] Nan F, Wu J, Qi F, Liu Y, Ngai T, Ma G. Uniform chitosan-coated alginate particles as emulsifiers for preparation of stable Pickering emulsions with stimulus dependence. Colloids and Surfaces. A, Physicochemical and Engineering Aspects, 2014, 456: 246–252

[40] Qi F, Wu J, Yang T Y, Ma G H, Su Z G. Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification. Acta Biomaterialia, 2014, 10(10): 4247–4256

[41] Rawat A, Stippler E, Shah V P, Burgess D J. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. International Journal of Pharmaceutics, 2011, 420(2): 198–205

[42] Jaworek A. Micro- and nanoparticle production by electrospraying. Powder Technology, 2007, 176(1): 18–35

[43] Zhang M, Ma Y, Li R, Zeng J, Li Z, Tang Y, Sun D. RhBMP-2-loaded Poly(lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for protein delivery. Journal of Biomaterials Science. Polymer Edition, 2017, 28(18): 2205–2219

[44] Della Porta G, Campardelli R, Cricchio V, Oliva F, Maffulli N, Reverchon E. Injectable PLGA/hydroxyapatite/chitosan microcapsules produced by supercritical emulsion extraction technology: An in vitro study on teriparatide/gentamicin controlled release. Journal of Pharmaceutical Sciences, 2016, 105(7): 2164–2172

[45] Falco N, Reverchon E, Della Porta G. Injectable PLGA/hydrocortisone formulation produced by continuous supercritical emulsion extraction. International Journal of Pharmaceutics, 2013, 441(1-2): 589–597

[46] Della Porta G, Campardelli R, Reverchon E. Monodisperse biopolymer nanoparticles by continuous supercritical emulsion extraction. Journal of Supercritical Fluids, 2013, 76: 67–73

[47] Campardelli R, Della Porta G, Gomez V, Irusta S, Reverchon E, Santamaria J. Encapsulation of titanium dioxide nanoparticles in PLA microspheres using supercritical emulsion extraction to produce bactericidal nanocomposites. Journal of Nanoparticle Research, 2013, 15(10): 1987–1997

[48] Della Porta G, Falco N, Giordano E, Reverchon E. PLGA microspheres by supercritical emulsion extraction: A study on insulin release in myoblast culture. Journal of Biomaterials Science. Polymer Edition, 2013, 24(16): 1831–1847

[49] Della Porta G, Nguyen B N, Campardelli R, Reverchon E, Fisher J P. Synergistic effect of sustained release of growth factors and dynamic culture on osteoblastic differentiation of mesenchymal stem cells. Journal of Biomedical Materials Research. Part A, 2015, 103(6): 2161–2171

[50] Campardelli R, Della Porta G, Gomez L, Irusta S, Reverchon E, Santamaria J. Au-PLA nanocomposites for photothermally controlled drug delivery. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 2014, 2(4): 409–417

[51] Jiang W L, Schwendeman S P. Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Molecular Pharmaceutics, 2008, 5(5): 808–817

[52] Liu Z Q, Li X, Xiu B S, Duan C M, Li J X, Zhang X H, Yang X Q, Dai W H, Johnson H, Zhang H Q, A novel and simple preparative method for uniform-sized PLGA microspheres: Preliminary application in antitubercular drug delivery. Colloids and Surfaces. B, Biointerfaces, 2016, 145: 679–687

[53] Hung L H, Teh S Y, Jester J, Lee A P. PLGA micro/nanosphere synthesis by droplet microfluidic solvent evaporation and extraction approaches. Lab on a Chip, 2010, 10(14): 1820–1825

[54] Wei Y, Wang Y X, Wang L Y, Hao D X, Ma G H. Fabrication strategy for amphiphilic microcapsules with narrow size distribution by premix membrane emulsification. Colloids and Surfaces. B, Biointerfaces, 2011, 87(2): 399–408

[55] Crowley M M, Zhang F, Repka M A, Thumma S, Upadhye S B, Battu S K, McGinity J W, Martin C. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Development and Industrial Pharmacy, 2007, 33(9): 909–926

[56] Guo Y, Yang Y, He L, Sun R, Pu C, Xie B, He H, Zhang Y, Yin T, Wang Y, Tang X. Injectable sustained-release depots of PLGA microspheres for insoluble drugs prepared by hot-melt extrusion. Pharmaceutical Research, 2017, 34(10): 2211–2222

[57] Bakri S J, Omar A F. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics, 2012, 28(5): 547–549

[58] Tice T. US Patent 2012/0156304 A1, 2012-06-21

[59] Zeigerson E. US Patent 8916196 B2, 2014-12-23

[60] Ma G H. Microencapsulation of protein drugs for drug delivery: Strategy, preparation, and applications. Journal of Controlled Release, 2014, 193: 324–340

[61] Qi F, Yang L Q, Wu J, Ma G H, Su Z G. Microcosmic mechanism of dication for inhibiting acylation of acidic peptide. Pharmaceutical Research, 2015, 32(7): 2310–2317

[62] Liu R, Ma G H, Meng F T, Su Z G. Preparation of uniform-sized PLA microcapsules by combining Shirasu Porous Glass membrane emulsification technique and multiple emulsion-solvent evaporation method. Journal of Controlled Release, 2005, 103(1): 31–43

[63] Liu R, Ma G H, Wan Y H, Su Z G. Influence of process parameters on the size distribution of PLA microcapsules prepared by combining membrane emulsification technique and double emulsion-solvent evaporation method. Colloids and Surfaces. B, Biointerfaces, 2005, 45(3-4): 144–153

[64] Liu R, Huang S S, Wan Y H, Ma G H, Su Z G. Preparation of insulin-loaded PLA/PLGA microcapsules by a novel membrane emulsification method and its release in vitro. Colloids and Surfaces. B, Biointerfaces, 2006, 51(1): 30–38

[65] Lloyd D M, Norton I T, Spyropoulos F. Processing effects during rotating membrane emulsification. Journal of Membrane Science, 2014, 466: 8–17

[66] Liang Y J, Yu H, Feng G, Zhuang L, Xi W, Ma M, Chen J, Gu N, Zhang Y. High-performance poly(lactic-co-glycolic acid)-magnetic microspheres prepared by rotating membrane emulsification for transcatheter arterial embolization and magnetic ablation in VX2 liver tumors. ACS Applied Materials & Interfaces, 2017, 9(50): 43478–43489

[67] Gupta V, Khan Y, Berkland C J, Laurencin C T, Detamore M S. Microsphere-based scaffolds in regenerative engineering. Annual Review of Biomedical Engineering, 2017, 19(1): 135–161

[68] Berkland C, Kim K K, Pack D W. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. Journal of Controlled Release, 2001, 73(1): 59–74

[69] Ye M, Kim S, Park K. Issues in long-term protein delivery using biodegradable microparticles. Journal of Controlled Release, 2010, 146(2): 241–260

[70] Kumar R, Palmieri M J Jr. Points to consider when establishing drug product specifications for parenteral microspheres. AAPS Journal, 2010, 12(1): 27–32

[71] Toguchi H. Sterility assurance of microspheres. Journal of Controlled Release, 1999, 62(1-2): 51–55

[72] Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Advanced Drug Delivery Reviews, 2008, 60(8): 939–954

[73] Wei Y, Wang Y X, Wang W, Ho S V, Qi F, Ma G H, Su Z G. Microcosmic mechanisms for protein incomplete release and stability of various amphiphilic mPEG-PLA microspheres. Langmuir, 2012, 28(39): 13984–13992

[74] Morlock M, Koll H, Winter G, Kissel T. Microencapsulation of Rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): Protein stability and the effects of stabilizing excipients. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 43(1): 29–36

[75] Cleland J L, Duenas E T, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. Journal of Controlled Release, 2001, 72(1-3): 13–24

[76] Meinel L, Illi O E, Zapf J, Malfanti M, Merkle H P, Gander B. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. Journal of Controlled Release, 2001, 70(1-2): 193–202

[77] Kang J, Wu F, Cai Y P, Xu M X, He M, Yuan W E. Development of recombinant human growth hormone (RhGH) sustained-release microspheres by a low temperature aqueous phase/aqueous phase emulsion method. European Journal of Pharmaceutical Sciences, 2014, 62: 141–147

[78] Hong X Y, Wei L M, Ma L Q, Chen Y H, Liu Z G, Yuan W. Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion. International Journal of Nanomedicine, 2013, 8: 2433–2441

[79] Sandor M, Riechel A, Kaplan I, Mathiowitz E. Effect of lecithin and MgCO₃ as additives on the enzymatic activity of carbonic anhydrase encapsulated in poly(lactide-co-glycolide) (PLGA) microspheres. Biochimica Et Biophysica Acta-General Subjects, 2002, 1570(1): 63–74

[80] Zhang Y, Schwendeman S P. Minimizing acylation of peptides in PLGA microspheres. Journal of Controlled Release, 2012, 162(1): 119–126

[81] Lucke A, Kiermaier J, Gopferich A. Peptide acylation by poly(alpha-hydroxy esters). Pharmaceutical Research, 2002, 19(2): 175–181

[82] Schwendeman S P, Sophocleous A M, Zhang Y. A new class of inhibitors of peptide sorption and acylation in PLGA. Journal of Controlled Release, 2009, 137(3-4): 179–184

[83] Pakulska M M, Donaghue I E, Obermeyer J M, Tuladhar A, McLaughlin C K, Shendruk T N, Shoichet M S. Encapsulation-free controlled release: Electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles. Science Advances, 2016, 2(5): e1600519–e1600519

[84] Rawat A, Burgess D J. USP apparatus 4 method for in vitro release testing of protein loaded microspheres. International Journal of Pharmaceutics, 2011, 409(1-2): 178–184

[85] Andhariya J V, Burgess D J. Recent advances in testing of microsphere drug delivery systems. Expert Opinion on Drug Delivery, 2016, 13(4): 593–608

[86] Zolnik B S, Leary P E, Burgess D J. Elevated temperature accelerated release testing of PLGA microspheres. Journal of Controlled Release, 2006, 112(3): 293–300

[87] ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1a (R2). 2003

[88] Zheng N, Sun D J D, Zou P, Jiang W L. Scientific and regulatory considerations for generic complex drug products containing nanomaterials. AAPS Journal, 2017, 19(3): 619–631

Acknowledgment

We thank the National Natural Science Foundation of China (Grant Nos. 21336010, 21776287 and 21576268) for the financial support, and Mr. Jianping Tan (Staidson (Beijing) Biopharmaceuticals Co., Ltd) for information support.

RIGHTS & PERMISSIONS

2018 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature